Similar analyses have been conducted using the CETP region to instrument lipid fractions and blood pressure (Sofat et al., 2010), using the IL6R region to assess the effect of interleukin 6 reduction on CHD risk (The Interleukin‐6 Receptor Mendelian Randomization Analysis [IL6R MR] Consortium, 2012), and using the HMGCR (Swerdlow et al., 2015) and PCSK9 regions (Schmidt et al., 2017) to explore potential effects of LDL‐cholesterol lowering treatments on body mass index and type 2 diabetes risk. This evidence concerns the gene HMGCR and type 2 diabetes mellitus.